← All Genmab A/s filings

Genmab A/s 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
GMAB
Genmab A/s
20-F: Genmab Accelerates Growth with Merus Acquisition, Bolsters Late-Stage Pipeline
Genmab reports strong 2025 financial results driven by product sales and royalties, while strategically expanding its late-stage pipeline through the acquisition of Merus N.V. and advancing key proprietary assets.
NASDAQ
GMAB
Genmab A/s
20-F: Genmab A/S Reports FY2024 Results, Highlights Pipeline Progress and Commercial Expansion
Genmab A/S files its 20-F report, detailing its financial performance for the year ended December 31, 2024, and outlining key strategic initiatives and pipeline advancements.
NASDAQ
GMAB
Genmab A/s
20-F: Genmab A/S Files 20-F Annual Report, Detailing Financial Performance and Business Overview
Genmab A/S releases its 20-F annual report, providing insights into its financial performance, business strategy, and key developments for the fiscal year ended December 31, 2023.